Please login to the form below

Not currently logged in
Email:
Password:

Hollingsworth leaves cancer charity for ABPI

Andrew Hollingsworth appointed policy manager at pharma industry body

Andrew Hollingsworth is to leave the third sector to join industry, moving from Cancer Research UK to the Association of the British Pharmaceutical Industry (ABPI).

Hollingsworth will join the UK pharma trade body on November 25 as policy manager. He leaves his role as public affairs manager at Cancer Research UK.

He will use his experience in the third sector in his new role, which will see him lead the ABPI's work to engage with patient groups. This includes the Patient Organisation Forum, which aims to identify mutual interest and improve collaboration between industry and patient organisations.

Hollingsworth also has industry experience spending more than five years at Novartis a senior manager, public affairs. This followed a period in politics as parliamentary assistant in the European Parliament.

Commenting on his new role, Hollingsworth said: “I am keen to develop the ABPI's engagement with patient organisations in an open, transparent and constructive dialogue."

13th November 2013

From: Research, Sales, Marketing, Regulatory, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics